Prolactin pp 317-339 | Cite as

In Vitro Effects of Prolactin on the Lympho-Hemopoietic System

  • Elizabeth L. Hooghe-Peters
  • Zeynep Dogusan
  • Robert Hooghe
Part of the Endocrine Updates book series (ENDO, volume 12)


Functional receptors for prolactin (PRL-R) are expressed on many cell types in various tissues, including leukocytes. The PRL-R belongs to the hemopoietin-cytokine receptor family. PRL itself is also expressed in the lympho-hemopoietic system (LHS) where it induces discrete effects. PRL thus qualifies as a cytokine. Effects on the LHS are modest in rodents and man and, though dispensable, PRL is clearly able to affect leukocyte physiology. The present contribution summarizes mainly recent in vitro studies on the role of PRL in the hemopoietic and in the immune systems.


Growth Hormone Systemic Lupus Erythematosus Prolactin Receptor Dwarf Mouse Vitro Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gala RR. Prolactin and growth hormone in the regulation of the immune system. Proc Soc Exp Biol Med 1991;198:513–27.PubMedGoogle Scholar
  2. 2.
    Arkins S, Dantzer R, Kelley KW. Somatolactogens, somatomedins, and immunity. J Dairy Sci 1993;76:2437–50.PubMedGoogle Scholar
  3. 3.
    Hooghe R, Delhase M, Vergani P, Malur A, Hooghe-Peters EL. Growth hormone and prolactin are paracrine growth and differentiation factors in the haemopoietic system. Immunol Today 1993;14:212–4.PubMedGoogle Scholar
  4. 4.
    Hooghe-Peters EL and Hooghe R Growth hormone, prolactin and IGF-I as lymphohematopoietic cytokines. RG Landes, Austin/Springer-Verlag, New York, 1995Google Scholar
  5. 5.
    Kooijman R, Hooghe-Peters EL, Hooghe R. Prolactin, growth hormone, and insulin-like growth factor-I in the immune system. Adv Immunol 1996;63:377–454PubMedGoogle Scholar
  6. 6.
    Yu-Lee L-y, Luo G, Moutoussamy S, Finidori J. Prolactin and growth hormone signal transduction in lymphohaemopoietic cells. Cell Mol Life Sci 1998;54: 1067–75.PubMedGoogle Scholar
  7. 7.
    Matera L Action of pituitary and lymphocyte prolactin. Neuro-immunomodulation 1997; 4:171–80.Google Scholar
  8. 8.
    Dorshkind K, Horseman, N. The roles of prolactin (PRL), growth hormone (GH), insulin-like growth factor-I (IGF-I), and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocrine Rev. 2000; 21:292–312.Google Scholar
  9. 9.
    Gout PW, Beer CT, Noble RL 1980 Prolactin-stimulated growth of cell cultures established from malignant Nb2 rat lymphomas. Cancer Res 40:2433–36.PubMedGoogle Scholar
  10. 10.
    Kincade, PW, Medina KL, Smithson G 1995 Sex hormones as negative regulators of lymphopoiesis. Immunol Rev 137:119–34.Google Scholar
  11. 11.
    McMurray RW, Keisler D, Izui S, Walker SE. Effects of parturition, suckling and pseudopregnancy on variables of disease activity in the B/W mouse model of systemic lupus erythematosus. J Rheumatol 1993;20:1143–51.PubMedGoogle Scholar
  12. 12.
    Blanco-Favela F, Quintal-Alvarez G, Leanos-Miranda A. Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol 1999;26:55–9.PubMedGoogle Scholar
  13. 13.
    McMurray RW, Weidensaul D, Allen SH, Walker SE. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 1995;22:2084–91.PubMedGoogle Scholar
  14. 14.
    Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Munoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 1998;7:414–9.PubMedGoogle Scholar
  15. 15.
    Funauchi M, Ikoma S, Enomoto H, Sugiyama M, Ohno M, Hamada K, Kanamaru A. Prolactin modulates the disease activity of systemic lupus erythematosus accompanied by prolactinoma. Clin Exp Rheumatol 1998;16:479–82.PubMedGoogle Scholar
  16. 16.
    MA, Welniak LA, Sun R, Tian Z-G, Henry M, Richards S, Raziuddin A, Longo DL, Murphy WJ. Prolactin exerts hematopoietic growth-promoting effectsin vivoand partially counteracts myelosuprression by azidothymidine. Exp Hematol 1999;27:811–16.PubMedGoogle Scholar
  17. 17.
    Richards SM, Murphy WJ. Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function. J. Neuroimmunol 2000, in press.Google Scholar
  18. 18.
    Matera L, Cutufia M, Geuna M, Contarini M, Buttiglieri S, Galin S, Fazzari A, Cavaliere C. Prolactin is an autocrine growth factor for the Jurkat human T-leukemic cell line. J Neuroimmunol 1997;79:12–21.PubMedGoogle Scholar
  19. 19.
    Matera L, Geuna M, Pastore C, Buttiglieri S, Gaidano G, Savarino A, Marengo S, Vonderhaar BK. Expression of prolactin and prolactin receptors by non-Hodgkin’s lymphoma cells. Int J Cancer 2000;85:124–30.PubMedGoogle Scholar
  20. 20.
    Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff, Dorshkind K. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 1997;16:6926–35.PubMedGoogle Scholar
  21. 21.
    Bouchard B, Ormandy CJ, Di Santo JP, Kelly PA Immune system development and function in prolactin receptor deficient mice. J Immunol 1999;163:576–82.PubMedGoogle Scholar
  22. 22.
    Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA 1998 Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225–68.PubMedGoogle Scholar
  23. 23.
    Shiu RPC, Elsholtz HP, Tanake T, Friesen FG, Gout PW, Geeer CT, Noble RL Receptor-mediated mitogen action of prolactin in a rat lymphoma cell line. Endocrinology 1983,113:159–65.PubMedGoogle Scholar
  24. 24.
    Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996;17:639–69.PubMedGoogle Scholar
  25. 25.
    Clevenger CV, Russell DH, Appasamy PM, Prystowsky MB. Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci U S A 1990;87:6460–4.PubMedGoogle Scholar
  26. 26.
    Nick JA, Young SK, Brown KK, Avdi NJ, Arndt PG, Suratt BT, Janes MS, Henson PM, Worthen GS. Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J Immunol 2000;164:2151–9.PubMedGoogle Scholar
  27. 27.
    Yamaoka K, Otsuka T, Niiro H, Arinobu Y, Niho Y, Hamasaki N, Izuhara K. Activation of STAT5 by lipopolysaccharide through granulocyte-macrophage colony-stimulating factor production in human monocytes. J Immunol 1998;160:838–45.PubMedGoogle Scholar
  28. 28.
    Fu YK, Arkins S, Fuh G, Cunningham BC, Wells JA, Fong S, Cronin MJ, Dantzer R, Kelley KW. Growth hormone augments superoxide anion secretion of human neutrophils by binding to the prolactin receptor. J Clin Invest 1992; 89:451–7.PubMedGoogle Scholar
  29. 29.
    Rayhel EJ, Fields TJ, Albright JW, Diamantstein T, Hughes JP. Interleukin 2 and a lactogen regulate proliferation and protein phosphorylation in Nb2 cells. Biochem J 1988;249:333–8.PubMedGoogle Scholar
  30. 30.
    Clevenger CV, Freier DO, Kline JB 1998 Prolactin receptor signal transduction in cells of the immune system. J Endocrinol 157:187–97.PubMedGoogle Scholar
  31. 31.
    Horseman ND, Yu-Lee LY. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. Endocr Rev 1994;15:627–49.PubMedGoogle Scholar
  32. 32.
    Hosokawa Y, Yang M, Kaneko S, Tanaka M, Nakashima K. Prolactin induces switching of T-cell receptor gene expression from alpha to gamma in rat Nb2 pre-T lymphoma cells. Biochem Biophys Res Commun 1996;220:958–62.PubMedGoogle Scholar
  33. 33.
    Montgomery DW, Krumenacker JS, Buckley AR. Prolactin stimulates phosphorylation of the human T-cell antigen receptor complex and ZAP-70 tyrosine kinase: a potential mechanism for its immunomodulation. Endocrinology 1998;139:811–4.PubMedGoogle Scholar
  34. 34.
    Krumenacker JS, Montgomery DW, Buckley DJ, Gout PW, Buckley AR. Prolactin receptor signaling: shared components with the T-cell antigen receptor in Nb2 lymphoma cells. Endocrine 1998;9:313–20.PubMedGoogle Scholar
  35. 35.
    Ali S, Edery M, Pellegrini I, Lesueur L, Paly J, Djiane J, Kelly PA. The Nb2 form of prolactin receptor is able to activate a milk protein gene promoter. Mol Endocrinol 1992;6:1242–8.PubMedGoogle Scholar
  36. 36.
    Krumenacker J, Buckley D, Leff M, McCormack J, de Jong G, Gout P, Reed J, Miyashita T, Magnuson N, Buckley A 1998 Prolactin-regulated apoptosis of Nb2 lymphoma cells: pim-1, bc1–2, and bax expression. Endocrine 9:163–70.PubMedGoogle Scholar
  37. 37.
    Leff MA, Buckley DJ, Krumenacker JS, Reed JC, Miyashita T, Buckley AR. Rapid modulation of the apoptosis regulatory genes, bd-2 and bax by prolactin in rat Nb2 lymphoma cells. Endocrinology 1996;137:5456–62.PubMedGoogle Scholar
  38. 38.
    Borg KE, Zhang M, Hegge D, Stephen RL, Buckley DJ, Magnuson NS, Buckley AR. Prolactin regulation of pim-1 expression: positive and negative promoter elements. Endocrinology 1999;140:5659–68.PubMedGoogle Scholar
  39. 39.
    Weimann E, Baixeras E, Zamzami N, Kelly PA. Prolactin blocks glucocorticoid induced cell death by inhibiting the disruption of the mitochondrial membrane. Leuk Res 1999;23:751–62.PubMedGoogle Scholar
  40. 40.
    Witorsch RJ, Day EB, Lavoie HA, Hashemi N, Taylor JK. Comparison of glucocorticoid-induced effects in prolactin-dependent and autonomous rat Nb2 lymphoma cells. Proc Soc Exp Biol Med 1993;203:454–60.PubMedGoogle Scholar
  41. 41.
    Camarillo IG, Linebaugh BE, Rillema JA. Differential tyrosyl-phosphorylation of multiple mitogen-activated protein kinase isoforms in response to prolactin in Nb2 lymphoma cells. Proc Soc Exp Biol Med 1997;215:198–202.PubMedGoogle Scholar
  42. 42.
    Yu TX, Rillema JA. The MEK inhibitor PD 098059 inhibits prolactin-induced Nb2 cell mitogenesis but not milk product synthesis in cultured mouse mammary tissues. Biochim Biophys Acta 1998;1448:126–34.PubMedGoogle Scholar
  43. 43.
    Erwin RA, Kirken RA, Malabarba MG, Farrar WL, Rui H. Prolactin activates Ras via signaling proteins SHC, growth factor receptor bound 2, and son of sevenless. Endocrinology 1995;136:3512–8.PubMedGoogle Scholar
  44. 44.
    Clevenger CV, Ngo W, Sokol DL, Luger SM, Gewirtz AM. Vav is necessary for prolactin-stimulated proliferation and is translocated into the nucleus of a T-cell line. J Biol Chem 1995;270:13246–53.PubMedGoogle Scholar
  45. 45.
    Hunter S, Burton EA, Wu SC, Anderson SM. Fyn associates with Cbl and phosphorylates tyrosine 731 in Cbl, a binding site for phosphatidylinositol 3-kinase. J Biol Chem 1999;274:2097–106.PubMedGoogle Scholar
  46. 46.
    Too CK, Knee R, Pinette AL, Li AW, Murphy PR. Prolactin induces expression of FGF-2 and a novel FGF-responsive NonO/p54nrb-related mRNA in rat lymphoma cells. Mol Cell Endocrinol 1998;137:187–95.PubMedGoogle Scholar
  47. 47.
    Nemeth E, Bole-Feysot C, Tashima LS. Suppression subtractive hybridization (SSH) identifies prolactin stimulation of p38 MAP kinase gene expression in Nb2 T lymphoma cells: molecular cloning of rat p38 MAP kinase. J Mol Endocrinol 1998;20:151–6.PubMedGoogle Scholar
  48. 48.
    Duncan GS, Mittrucker HW, Kagi D, Matsuyama T, Mak TW. The trans-cription factor interferon regulatory factor-1 is essential for natural killer cell function in vivo. J Exp Med. 1996;184:2043–8.PubMedGoogle Scholar
  49. 49.
    Berwaer M, Martial JA, Davis JR. Characterization of an up-stream promoter directing extrapituitary expression of the human prolactin gene. Mol Endocrinol 1994;8:635–42.PubMedGoogle Scholar
  50. 50.
    Gellersen B, Kempf R, Telgmann R, DiMattia GE 1994 Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endomedtrial stroma. Mol Endocrinol 8:356–73.PubMedGoogle Scholar
  51. 51.
    Reem GH, Ray DW, Davis JR. The human prolactin gene upstream promoter is regulated in lymphoid cells by activators of T-cells and by cAMP. J Mol Endocrinol 1999;22:285–92.PubMedGoogle Scholar
  52. 52.
    DiMattia GE, Gellersen B, Bohnet HG, Friesen HG. A human B-lympho-blastoid cell line produces prolactin. Endocrinology 1988;122:2508–17.PubMedGoogle Scholar
  53. 53.
    Touraine P, Leite de Moraes MC, Dardenne M, Kelly PA. Expression of short and long forms of prolactin receptor in murine lymphoid tissues. Mol Cell Endocrinol 1994;104:183–90.PubMedGoogle Scholar
  54. 54.
    Pellegrini I, Lebrun JJ, Ali S, Kelly PA 1992 Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinology 6:1023–1031Google Scholar
  55. 55.
    Delhase M, Vergani P, Malur A, Hooghe-Peters EL, Hooghe RJ. The transcription factor Pit-1/GHF-1 is expressed in hemopoietic and lymphoid tissues. Eur J Immunol. 1993;23:951–5.PubMedGoogle Scholar
  56. 56.
    Wu H, Devi R, Malarkey WB. Expression and localization of prolactin messenger ribonucleic acid in the human immune system. Endocrinology 1996;137:349–53.PubMedGoogle Scholar
  57. 57.
    Gingras MC, Margolin JF.Differential expression of multiple unexpected genes during U937 cell and macrophage differentiation detected by suppressive subtractive hybridization. Exp Hematol 2000;28:65–76.PubMedGoogle Scholar
  58. 58.
    Cavaco B, Leite V, Santos MA, Arranhado E, Sobrinho LG. Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. J Clin Endocrinol Metab 1995;80:2342–6.PubMedGoogle Scholar
  59. 59.
    Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf)1999;51:119–26.Google Scholar
  60. 60.
    Hattori N, Inagaki C. Immunological aspects of human growth hormone and prolactin. Domest Anim Endocrinol 1998;15:371–5.PubMedGoogle Scholar
  61. 61.
    Bonhoff A, Vuille JC, Gomez F, Gellersen B. Identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable PRL-IgG complex. Exp Clin Endocrinol 1995;103:252–5.Google Scholar
  62. 62.
    Walker AM, Montgomery DW, Saraiya S, Ho TW, Garewal HS, Wilson J, Lorand L. Prolactin-immunoglobulin G complexes from human serum act as costimulatory ligands causing proliferation of malignant B lymphocytes. Proc Natl Acad Sci U S A 1995;92:3278–82.PubMedGoogle Scholar
  63. 63.
    Wang YF, Liu JW, Mamidi M, Walker AM. Identification of the major site of rat prolactin phosphorylation as serine 177. J Biol Chem. 1996;271:2462–9.PubMedGoogle Scholar
  64. 64.
    Chen TJ, Kuo CB, Tsai KF, Liu JW, Chen DY, Walker AM. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. End¨®crinology. 1998;139:609–16.Google Scholar
  65. 65.
    Ellis LA, Picciano MF. Bioactive and immunoreactive prolactin variants in human milk. Endocrinology 1995;136:2711–20PubMedGoogle Scholar
  66. 66.
    Jurcovicova J, Krueger KS, Rokyta R. Effect of glycosylated and non-glycosylated prolactin on the proliferation of normal human lymphocytes. Physiol Res 1997;46:199–201.PubMedGoogle Scholar
  67. 67.
    Goffin V, Binart N, Clement-Lacroix P, Bouchard B, Bole-Feysot C, Edery M, Lucas BK, Touraine P, Pezet A, Maaskant R, Pichard C, Helloco C, Baran N, Favre H, Bemichtein S, Allamando A, Ormandy C, Kelly PA. From the molecular biology of prolactin and its receptor to the lessons learned from knockout mice models. Genet Anal 1999;15:189–201.PubMedGoogle Scholar
  68. 68.
    Royster M, Driscoll P, Kelly PA, Freemark M. The prolactin receptor in the fetal rat: cellular localization of messenger ribonucleic acid, immunoreactive protein, and ligand-binding activity and induction of expression in late gestation. Endocrinology 1995;136:3892–900PubMedGoogle Scholar
  69. 69.
    Ouhtit A, Morel G, Kelly PA. Visualization of gene expression of short and long forms of prolactin receptor in the rat. Endocrinology 1993;133:135–44.PubMedGoogle Scholar
  70. 70.
    McAveney KM, Gimble JM, Yu-Lee L. Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology 1996;137:5723–6.PubMedGoogle Scholar
  71. 71.
    Koh CY, Phillips JT. Prolactin receptor expression by lymphoid tissues in normal and immunized rats. Mol Cell Endocrinol. 1993;92:R21–5.PubMedGoogle Scholar
  72. 72.
    Gagnerault MC, Touraine P, Savino W, Kelly PA, Dardenne M. Expression of prolactin receptors in murine lymphoid cells in normal and autoimmune situations. J Immunol 1993;150:5673–81.PubMedGoogle Scholar
  73. 73.
    Gala RR, Shevach EM. Identification by analytical flow cytometry of prolactin receptors on immunocompetent cell populations in the mouse. Endocrinology 1993; 133:1617–23.PubMedGoogle Scholar
  74. 74.
    Kline JB, Roehrs H, Clevenger CV. Functional characterization of the intermediate isoform of the human prolactin receptor. J Biol Chem 1999;274:35461–8.PubMedGoogle Scholar
  75. 75.
    Bresson J-L, Sébastien J, Gagnerault M-C, Kayser C, Beressi N, Wu Z, Kinet S, Dardenne M, Postel-Vinay, M-C 1999 Growth hormone (GH) and prolactin receptors in human peripheral blood mononulcear cells: relation with age and GH-binding protein. Endocrinology 140:3203–3209PubMedGoogle Scholar
  76. 76.
    Dardenne M, de Moraes M do C, Kelly PA, Gagnerault MC. Prolactin receptor expression in human hematopoietic tissues analyzed by flow cytofluorometry. Endocrinology. 1994;134:2108–14.PubMedGoogle Scholar
  77. 77.
    Matera L, Muccioli G, Cesano A, Bellussi A, Gennazzani E. Prolactin receptors on large granular lymphocytes: dual recognition by cyclosporin A. Brain Behav Immunol 1988;2:1–10.Google Scholar
  78. 78.
    Nagy E, Berczi I. Hypophysectomized rats depend on residual prolactin for survival. Endocrinology. 1991; 128:2776–84.PubMedGoogle Scholar
  79. 79.
    Morikawa K, Oseko F, Morikawa S 1993 Immunosuppressive properties of bromocriptine on human B lymphocyte functionin vitro.Clin Exp Immunol 93:200–5.PubMedGoogle Scholar
  80. 80.
    Morikawa K, Oseko F, Morikawa S 1994 Immunosupressive activity of bromocriptine on human T lymphocyte functionin vitro.Clin Exp Immunol 95:514–18.PubMedGoogle Scholar
  81. 81.
    Wennbo H, Kindblom J, Isaksson OG, Tomell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 1997;138:4410–5.PubMedGoogle Scholar
  82. 82.
    Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, Hoffmeyer A, van Deursen J, Sangster MY, Bunting KD, Grosveld GC, Ihle JN. StatS is required for IL-2induced cell cycle progression of peripheral T cells. Immunity 1999;10:249–59.PubMedGoogle Scholar
  83. 83.
    Meli R, Raso GM, Gualillo 0, Pacilio M, Di Carlo R. Prolactin modulation of nitric oxide and TNF-alpha production by peripheral neutrophils in rats. Life Sci 1997;61(14):1395–403.PubMedGoogle Scholar
  84. 84.
    Bellone G, Rollino C, Borsa S, Ferrero I, Martina G, Carbone A, Mareschi K, Quarello F, Piccoli G, Emanuelli G, Matera L. Association Between Elevated Prolactin Levels and Circulating Erythroid Precursors in Dialyzed Patients. Proc Soc Exp Biol Med 2000;223:367–71.PubMedGoogle Scholar
  85. 85.
    Zimmer JP, Garza C, Heller ME, Butte N, Goldman AS. Relationship between serum prolactin, lactation and changes in maternal blood B-cell (CD 19+) percents during the first 8 months post-partum. J Reprod Immunol 1996;30:81–95.PubMedGoogle Scholar
  86. 86.
    Zimmer JP, Garza C, Butte NF, Goldman AS. Maternal blood B-cell (CD19+) percentages and serum immunoglobulin concentrations correlate with breast-feeding behavior and serum prolactin concentration. Am J Reprod Immunol 1998;40:57–62.PubMedGoogle Scholar
  87. 87.
    Köller M, Kotzmann H, Clodi M, Riedl M, Luger A Effect of elevated serum prolactin concentrations on the immunophenotype of human lymphocytes, mitogen-induced proliferation and phagocytic activity of polymorphonuclear cells. Eur J Clin Invest 1997;27:662–6.PubMedGoogle Scholar
  88. 88.
    Krause I, Blumenfeld Z, Malchinsky M, Cohen S, Blank M, Eldor A, Weksler B, Schweitzer K, Shoenfeld Y. Anti-endothelial cell antibodies in the sera of hyperprolactinemic women. Lupus 1998;7:377–82.PubMedGoogle Scholar
  89. 89.
    Ferrari C, Boghen M, Paracchi A, Rampini P, Raiteri F, Benco R, Romussi M, Codecasa F, Mucci M, Bianco M. Thyroid autoimmunity in hyperprolactinaemic disorders. Acta Endocrinol 1983;104:35–41.PubMedGoogle Scholar
  90. 90.
    Neidhart M. Bromocriptine microcapsules inhibit ornithine decarboxylase activity induced by Freund’s complete adjuvant in lymphoid tissues of male rats. Endocrinology 1989;125:2846–52.PubMedGoogle Scholar
  91. 91.
    Perez Castro C, Penalva R, Paez Pereda M, Renner U, Reul JMHM, Stalla GK, Holsboer F, Arzt E 1999 Early activation of thyrotropin-releasing hormone and prolactin plays a critical role during a T cell-dependent immune response. Endocrinology 140:690–7.Google Scholar
  92. 92.
    Bellone G, Geuna M, Carbone A, Silvestri S, Foa R, Emanuelli G, Matera L. Regulatory action of prolactin on thein vitrogrowth of CD34+ve human hemopoietic progenitor cells. J Cell Physiol 1995;163:221–31.PubMedGoogle Scholar
  93. 93.
    Bellone G, Astarita P, Artusio E, Silvestri S, Mareschi K, Turletti A, Buttiglieri S, Emanuelli G, Matera L. Bone marrow stroma-derived prolactin is involved in basal and platelet-activating factor-stimulatedin vitroerythropoiesis. Blood 1997;90:21–7.PubMedGoogle Scholar
  94. 94.
    Lin J, Linzer DI. Induction of megakaryocyte differentiation by a novel pregnancy-specific hormone. J Biol Chem. 1999;274:21485–9.PubMedGoogle Scholar
  95. 95.
    Socolovsky M, Fallon AE, Lodish HF. The prolactin receptor rescues EpoR-/- erythroid progenitors and replaces EpoR in a synergistic interaction with c-kit. Blood 1998;92:1491–6.PubMedGoogle Scholar
  96. 96.
    Warwick-Davies J, Lowrie DB, Cole N. Growth hormone is a human macrophage activating factor. Priming of human monocytes for enhanced release of H2O2. J Immunol. 1995;154:1909–18.PubMedGoogle Scholar
  97. 97.
    Matera L, Galetto A, Geuna M, Vekemans K, Ricotti E, Contarini F, Moro F, Basso G. Individual and combined effect of GM-CSF and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions. J Neuroimmunol 2000, in press.Google Scholar
  98. 98.
    Matera L, Mori, M. Different cooperation of prolactin with IL-2 and IL-12 on the production of IFN-y by NK and T cells. Ann. NY Acad Sc. 2000, in press.Google Scholar
  99. 99.
    Morales P, Carretero MV, Geronimo H, Copin SG, Gaspar ML, Marcos MA, Martin-Perez J. Influence of prolactin on the differentiation of mouse B-lymphoid precursors. Cell Growth Differ 1999;10:583–90.PubMedGoogle Scholar
  100. 100.
    Matera L, Cesano A, Bellone G, Oberholtzer E. Modulatory effect of prolactin on the resting and mitogen-induced activity of T, B, and NK lymphocytes. Brain Behav Immun 1992;6:409–17.PubMedGoogle Scholar
  101. 101.
    Richards SM, Garman RD, Keyes L, Kavanagh B, McPherson IM. Prolactin is an antagonist of TGF-beta activity and promotes proliferation of murine B cell hybridomas. Cell Immunol 1998;184:85–91.PubMedGoogle Scholar
  102. 102.
    Lahat N, Miller A, Shtiller R, Touby E. Differential effects of prolactin upon activation and differentiation of human B lymphocytes. J Neuroimmunol 1993;47:35–40.PubMedGoogle Scholar
  103. 103.
    Clevenger CV, Sillman AL, Hanley-Hyde J, Prystowsky MB. Requirement for prolactin during cell cycle regulated gene expression in cloned T-lymphocytes. Endocrinology. 1992;130:3216–22.PubMedGoogle Scholar
  104. 104.
    Belkowski SM, Levine JE, Prystowsky MB. Requirement of PI3-kinase activity for the nuclear transport of prolactin in cloned murine T lymphocytes. J Neuroimmunol 1999;94:40–7.PubMedGoogle Scholar
  105. 105.
    Mukherjee P, Mastro AM, Hymer WC Prolactin induction of interleukin-2 receptors on rat splenic lymphocytes. Endocrinology 1990;126:88–94.PubMedGoogle Scholar
  106. 106.
    Viselli SM, Stanek EM, Mukherjee P, Hymer WC, Mastro AM Prolactin-induced mitogenesis of lymphocytes from ovariectomized rats. Endocrinology 1991;129:983–90.PubMedGoogle Scholar
  107. 107.
    John S, Robbins CM, Leonard WJ. An IL-2 response element in the human IL-2 receptor alpha chain promoter is a composite element that binds StatS, Elf-1, HMG-I(Y) and a GATA family protein. EMBO J 1996;15:5627–35.PubMedGoogle Scholar
  108. 108.
    Cesario TC, Yousefi S, Carandang G, Sadati N, Le J, Vaziri N. Enhanced yields of gamma interferon in prolactin treated human peripheral blood mononuclear cells. Proc Soc Exp Biol Med 1994;205:89–95.PubMedGoogle Scholar
  109. 109.
    Thellin O, Coumans B, Devos S, Hooghe-Peters EL, Zorzi W, Igout A, Heinen E, Hooghe R. Limited effects of placental and pituitary growth hormone on cytokine expression in vitro. Eur.Cytokine Network 2000; 11: in press.Google Scholar
  110. 110.
    Matera L, Bellone G, Lebrun JJ, Kelly PA, Hooghe-Peters EL, Di Celle PF, Foa R, Contarini M, Avanzi G, Asnaghi V. Role of prolactin in thein vitrodevelopment of interleukin-2-driven anti-tumoural lymphokine-activated killer cells. Immunology 1996;89:619–26.PubMedGoogle Scholar
  111. 111.
    Müller H, Liu B, Croy BA, Head JR, Hunt JS, Dai G, Soares MJ. Uterine natural killer cells are targets for a trophoblast cell-specific cytokine, prolactin-like protein A. Endocrinology 1999;140:2711–20.PubMedGoogle Scholar
  112. 112.
    Oberholtzer E, Contarini M, Veglia F, Cossarizza A, Franceschi C, Geuna M, Provinciali M, Di Stefano G, Sissom J, Brizzi MF, Pegoraro L, Matera L. Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors. Adv Neuroimmunol 1996;6:233–47.PubMedGoogle Scholar
  113. 113.
    Nagafuchi H, Suzuki N, Kaneko A, Asai T, Sakane T. Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 1999;26:1890–900.PubMedGoogle Scholar
  114. 114.
    McAveney KM, Gimble JM, Yu-Lee L 1996 Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology 137:5723–26.PubMedGoogle Scholar
  115. 115.
    Nanbu-Wakao R, Fujitani Y, Masuho Y, Muramatu M, Wakao H. Prolactin enhances CCAAT enhancer-binding protein-beta (C/EBP beta) and peroxisome proliferatoractivated receptor gamma (PPAR gamma)messenger RNA expression and stimulates adipogenic conversion ofNIH-3T3 cells. Mol Endocrinol 2000;14:307–16.PubMedGoogle Scholar
  116. 116.
    Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PP. AR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol. 2000;164:1364–71.PubMedGoogle Scholar
  117. 117.
    Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Riffling SR, Denhardt DT, Glimcher MJ, Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860–4.PubMedGoogle Scholar
  118. 118.
    Baik MG, Lee MJ, Choi YJ. Gene expression during involution of mammary gland (review). Int J Mol Med. 1998;2:39–44.PubMedGoogle Scholar
  119. 119.
    Dogusan Z, Book ML, Verdood P, Yu-Lee L-y, Hooghe-Peters EL. Prolactin activates interferon regulatory factor-1 expression in normal lympho-hemopoietic cells. Eur. Cytokine Network, 2000,11:in press.Google Scholar
  120. 120.
    Dogusan Z, Hooghe-Peters EL, Berus D, Velkeniers B, Hooghe R. Expression of SOCS genes in normal and leukemic human leukocytes stimulated by prolactin, growth hormone and cytokines. J Neuroimmunol 2000, in press.Google Scholar
  121. 121.
    Zhu T, Lobie PE. Janus kinase 2-dependent activation of p38 mitogen-activated protein kinase by growth hormone. Resultant transcriptional activation of ATF-2 and CHOP, cytoskeletal re-organization and mitogenesis. J Biol Chem 2000;275:2103–14.PubMedGoogle Scholar
  122. 122.
    Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A. 1995 A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14: 2816–26.PubMedGoogle Scholar
  123. 123.
    Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyajima A, Yoshimura 1997 CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89: 3148–54.PubMedGoogle Scholar
  124. 124.
    Hilton DJ 1999 Negative regulators of cytokine signal transduction. Cell Mol Life Sci 1999 55: 1568–77.Google Scholar
  125. 125.
    Verdier F, Rabionet R, Gouilleux F, Beisenherz-Huss C, Varlet P, Muller O, Mayeux P, Lacombe C, Gisselbrecht S, Chretien S 1998 A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B Mol Cell Biol 18: 5852–60.Google Scholar
  126. 126.
    Matuoka K, Miki H, Takahashi K, Takenawa T 1997 A novel ligand for an SH3 domain of the adaptor protein Nck bears an SH2 domain and nuclear signaling motifs. Biochem Biophys Res Commun 239: 488–92.Google Scholar
  127. 127.
    Heiman D, Sandowski Y, Cohen Y, Matsumoto A, Yoshimura A, Merchav S, Gertler A. 1998 Cytokine-inducible SH2 protein (CIS3) and JAK2 binding protein (JAB) abolish prolactin receptor-mediated STAT5 signaling. FEBS Lett 441: 287–91.Google Scholar
  128. 128.
    Pezet A, Favre H, Kelly PA, Edery M. Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. J Biol Chem 1999;274:24497–502.PubMedGoogle Scholar
  129. 129.
    Dickensheets HL, Venkataraman C, Schindler U, Donnelly RP. 1999. Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc Natl Acad Sci U S A 96: 10800–5.PubMedGoogle Scholar
  130. 130.
    Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donnelly RP, Lamer AC, Finbloom DS 1999 Interleukin-10 inhibits expression of both interferon alpha-and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93: 1456–63.PubMedGoogle Scholar
  131. 131.
    Zellweger R, Zhu XH, Wichmann MW, Ayala A, DeMaso CM, Chaudry IH. Prolactin administration following hemorrhagic shock improves macrophage cytokine release capacity and decreases mortality from subsequent sepsis. J Immunol. 1996;157:5748–54.PubMedGoogle Scholar
  132. 132.
    Stoecklin E, Wissler M, Schaetzle D, Pfitzner E, Groner B. Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol. 1999;69:195–204.PubMedGoogle Scholar
  133. 133.
    Stevens FR, Hajeer A, John S, Thomson W, Worthington J, Davis JR, Oilier WE. The Bg/II polymorphism of the human prolactin gene lies within intron C and can be detected by PCR/RFLP. Eur J Immunogenet 1999;26:261–3.PubMedGoogle Scholar
  134. 134.
    Fuh G, Wells JA. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem. 1995;270:13133–7.PubMedGoogle Scholar
  135. 135.
    Goupille O, Barnier JV, Guibert B, Paly J, Djiane J. Effect of PRL on MAPK activation: negative regulatory role of the C-terminal part of the PRL receptor. Mol Cell Endocrinol. 2000;159:133–46.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Elizabeth L. Hooghe-Peters
    • 1
    • 2
  • Zeynep Dogusan
    • 1
    • 2
  • Robert Hooghe
    • 1
    • 2
  1. 1.Free University of Brussels (V. U.B.)BrusselsBelgium
  2. 2.Flemish Institute for Technological Research (VITO)MolBelgium

Personalised recommendations